“…Besides having specific clinical features, cancer‐related CI also has specific pathogenesis that is worth exploring. Previous studies have found that in addition to the fact that some cancers can directly lead to CI (Budincevic et al., 2016 , Zheng et al., 2014 ), most cancer‐related CI is associated with hypercoagulability based on elevated serum D‐dimer level (Shen et al., 2020 , Rosenberg et al., 2020 , Gon et al., 2017 ). However, as has been found in other studies on the pathogenesis of cancer‐related CI, although patients are considered to be hypercoagulable, routine coagulation tests, such as thrombin time, PT, APTT, and INR, are normal in most patients with cancer‐related CI, suggesting that the tests are inadequate to assess blood clotting (Cheng et al., 2021 , Quan et al., 2020 , Qin et al., 2018 ).…”